<DOC>
	<DOCNO>NCT02008578</DOCNO>
	<brief_summary>The purpose randomize , double-blind , placebo-controlled trial intravenous hyperimmune immunoglobulin ( Flu-IVIG ) individual influenza A B determine pharmacokinetic ( PK ) profile Flu-IVIG ass whether antibody level observe follow Flu-IVIG transfusion similar predict . This pilot study inform large study power compare Flu-IVIG placebo efficacy .</brief_summary>
	<brief_title>Anti-Influenza Hyperimmune Intravenous Immunoglobulin Pilot Study ( INSIGHT 005 : Flu-IVIG Pilot )</brief_title>
	<detailed_description>The purpose randomize , double-blind , placebo-controlled trial intravenous hyperimmune immunoglobulin ( Flu-IVIG ) individual influenza A B determine pharmacokinetic ( PK ) profile Flu-IVIG ass whether antibody level observe follow Flu-IVIG transfusion similar predict . This pilot study inform large study power compare Flu-IVIG placebo efficacy . In addition inform Flu-IVIG dosing require clinical outcome trial , pilot study compare influenza antibody level safety study participant randomly assign Flu-IVIG assign placebo , assess feasibility enrollment , evaluate randomization blinding procedure , possibly obtain preliminary data efficacy may use inform sample size study procedure clinical outcome study .</detailed_description>
	<mesh_term>Influenza , Human</mesh_term>
	<mesh_term>Immunoglobulins , Intravenous</mesh_term>
	<mesh_term>gamma-Globulins</mesh_term>
	<mesh_term>Rho ( D ) Immune Globulin</mesh_term>
	<mesh_term>Immunoglobulins</mesh_term>
	<mesh_term>Antibodies</mesh_term>
	<criteria>INCLUSION CRITERIA : 1 . Signed informed consent 2 . Age great equal 18 year age 3 . Outpatients inpatient PCR rapid Ag positive influenza A B preferably within 24 hour later 6 day symptom onset 4 . Onset illness 6 day randomization , define patient first experience least one respiratory symptom , constitutional symptom fever 5 . For woman childbearing potential , negative pregnancy test within one day prior randomization willingness abstain sexual intercourse use least 1 form hormonal barrier contraception Day 28 study 6 . Willingness blood respiratory sample obtain stored EXCLUSION CRITERIA : 1 . If hospitalize , admit reason influenza complication influenza 2 . Women pregnant breastfeed 3 . Strong clinical evidence ( judgment site investigator ) etiology illness primarily bacterial origin . 4 . Prior treatment investigational drug therapy within 30 day prior screen 5 . History allergic reaction blood plasma product ( judged investigator ) 6 . Known IgA deficiency 7 . A preexist condition use medication , opinion investigator , may place individual substantially increase risk thrombosis ( e.g. , cryoglobulinemia , severe refractory hypertriglyceridemia , clinically significant monoclonal gammopathy ) 8 . Serum creatinine great equal 1.5 x ULN know active kidney disease may affect drug pharmacokinetics ( e.g. , nephrotic syndrome ) 9 . Presence preexist illness , opinion investigator , would place individual unreasonably increase risk participation study 10 . Patients , judgment investigator , unlikely comply requirement protocol 11 . Medical condition receipt 500mL volume may dangerous patient ( e.g. , decompensated congestive heart failure ) 12 . Suspicion infection due influenza strain subtype A ( H1N1 ) pdm09 , H3N2 , influenza B ( e.g. , H5N1 , H7N9 )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Antiviral</keyword>
	<keyword>Adjunctive Therapy</keyword>
	<keyword>Antibody</keyword>
</DOC>